Cargando…

ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?

The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift as the number of genes associated with the disease risk and pathogenesis, and the cellular processes involved, continues to grow. Despite decades of intense research and over 50 potentially causative or disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mejzini, Rita, Flynn, Loren L., Pitout, Ianthe L., Fletcher, Sue, Wilton, Steve D., Akkari, P. Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909825/ https://www.ncbi.nlm.nih.gov/pubmed/31866818 http://dx.doi.org/10.3389/fnins.2019.01310

Ejemplares similares

Antisense-mediated splice intervention to treat human disease: the odyssey continues
por: Pitout, Ianthe, et al.
Publicado: (2019)

Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript
por: Flynn, Loren L., et al.
Publicado: (2018)

Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies
por: Flynn, Loren L., et al.
Publicado: (2021)

Structural Variants May Be a Source of Missing Heritability in sALS
por: Theunissen, Frances, et al.
Publicado: (2020)

Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Where are we now?
Publicado: (1977)

DNAzymes: Expanding the Potential of Nucleic Acid Therapeutics
por: Larcher, Leon M., et al.
Publicado: (2023)

Genetics of migraine: where are we now?
por: Grangeon, Lou, et al.
Publicado: (2023)

Improvements to Healthspan Through Environmental Enrichment and Lifestyle Interventions: Where Are We Now?
por: Queen, Nicholas J., et al.
Publicado: (2020)

MHC Restriction: Where Are We Now?
por: Zareie, Pirooz, et al.
Publicado: (2020)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

Genetic counseling globally: Where are we now?
por: Ormond, Kelly E., et al.
Publicado: (2018)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Geroprotectors as a therapeutic strategy for COPD – where are we now?
por: Miłkowska-Dymanowska, Joanna, et al.
Publicado: (2017)

The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?
por: Cleymaet, Robbert, et al.
Publicado: (2022)

High energy physics: where are we now?
por: Jaffe, R L
Publicado: (1985)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Pediatric SJS-TEN: Where are we now?
por: Ramien, Michele, et al.
Publicado: (2020)

Platelet-Rich Plasma: Where Are We Now and Where Are We Going?
por: Cole, Brian J., et al.
Publicado: (2010)

Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Ten Years for GHSP: Where Are We Now? Where Will We Go?
por: Bhutta, Zulfiqar A., et al.
Publicado: (2023)

Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023)

CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)

Pedunculopontine Nucleus Stimulation: Where are We Now and What Needs to be Done to Move the Field Forward?
por: Morita, Hokuto, et al.
Publicado: (2014)

Resistant Hypertension: Where are We Now and Where Do We Go from Here?
por: Pathan, Mansur K, et al.
Publicado: (2020)

Single Stranded Fully Modified-Phosphorothioate Oligonucleotides can Induce Structured Nuclear Inclusions, Alter Nuclear Protein Localization and Disturb the Transcriptome In Vitro
por: Flynn, Loren L., et al.
Publicado: (2022)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Depression research: where are we now?
por: Lee, Saebom, et al.
Publicado: (2010)

Personal workstations: Where are we now?
por: Willers, Ian Malcolm
Publicado: (1982)

Personal genomics: Where are we now?
por: Angrist, Misha
Publicado: (2016)

9. GFR - Where are We Now?
por: Delanghe, Joris R.
Publicado: (2009)

Calcaneal fractures: Where are we now?
por: Razik, Aisha, et al.
Publicado: (2017)

Intracranial Atherosclerosis: Where Are We Now?
por: Kim, Jong S.
Publicado: (2017)

Mindfulness in psychiatry – where are we now?
por: Groves, Paramabandhu
Publicado: (2016)

Microbiota and Obesity: Where Are We Now?
por: Ballini, Andrea, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jt6gggjv122d45doqa2kh9rilu